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Abstract
Disorders of sex development (DSD), ranging in severity from mild genital abnormalities to complete sex reversal, represent
a major concern for patients and their families. DSD are often due to disruption of the genetic programs that regulate
gonad development. Although some genes have been identified in these developmental pathways, the causative mutations
have not been identified in more than 50% 46,XY DSD cases. We used the Affymetrix Genome-Wide Human SNP Array 6.0 to
analyse copy number variation in 23 individuals with unexplained 46,XY DSD due to gonadal dysgenesis (GD). Here we
describe three discrete changes in copy number that are the likely cause of the GD. Firstly, we identified a large duplication
on the X chromosome that included DAX1 (NR0B1). Secondly, we identified a rearrangement that appears to affect a novel
gonad-specific regulatory region in a known testis gene, SOX9. Surprisingly this patient lacked any signs of campomelic
dysplasia, suggesting that the deletion affected expression of SOX9 only in the gonad. Functional analysis of potential SRY
binding sites within this deleted region identified five putative enhancers, suggesting that sequences additional to the
known SRY-binding TES enhancer influence human testis-specific SOX9 expression. Thirdly, we identified a small deletion
immediately downstream of GATA4, supporting a role for GATA4 in gonad development in humans. These CNV analyses
give new insights into the pathways involved in human gonad development and dysfunction, and suggest that
rearrangements of non-coding sequences disturbing gene regulation may account for significant proportion of DSD cases.
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Introduction
A defining point during embryogenesis is the commitment to
develop as male or female. In males this is initiated by the Y-linked
SRY gene, which leads to testis development. Ovarian develop-
ment occurs in the absence of the Y-linked SRY gene, and
ultimately results in a female phenotype. These developmental
pathways involve complex networks of genes, the precise
regulation of which is vital for the correct development of the
gonads and associated anatomical structures [1].
Disruption of these networks can lead to disorders of sex
development (DSD), which are congenital conditions with atypical
development of the chromosomal, gonadal or anatomical sex [2].
DSD can be divided into three etiological subclasses, namely
syndromic, disorders of androgen action, and gonadal dysgenesis
[3]. The focus here is on individuals with 46,XY DSD due to
gonadal dysgenesis (hereafter referred to as 46,XY GD).
Individuals with 46,XY complete gonadal dysgenesis (CGD) are
phenotypically female, have completely undeveloped streak
gonads, and are often not diagnosed until puberty when secondary
sexual characteristics fail to develop. Mutations in SRY and SOX9
account for approximately 20% of 46,XY CGD patients [4].
Causative mutations affecting several other genes have been
identified [5], including DAX1 (NR0B1)[6], SF1 (NR5A1)[7],
WNT4 [8], DHH [9] and MAP3K1[10]. Mutations in these genes
are responsible for fewer than 30% of cases [11] and little is known
about the underlying genetic basis in the remaining 50% of
patients.
Individuals with 46,XY partial gonadal dysgenesis (PGD) and
ovotesticular DSD have a phenotype that can range from a mildly
undervirilised male through ambiguous genitalia to a slightly
virilised female phenotype, depending on the amount of residual
testicular function present. The diagnosis is therefore usually made
at birth of the child with anomalous genitalia. In 46,XY ovarian
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17793DSD the phenotype is entirely female, including presence of
female gonads. A diagnosis may be made due to presentation with
early ovarian failure.
There have been intensive efforts in the last decade to identify
novel genes involved in gonad differentiation, using a range of
animal models [12,13]. Although a large number of candidate
genes have been identified, few mutations have been identified in
these genes in human DSD patients. Even less is known about the
gonad-specific regulation of these genes, although recent work has
identified one gonad-specific enhancer of SOX9 in the mouse[14].
It is currently unclear whether unexplained cases of DSD are due
to mutations in novel gonadal genes or mutations in the regulatory
regions of known gonadal genes.
The genetic basis of several diseases has been elucidated by rare
cases involving large, cytogenetically visible deletions or translo-
cations that identified specific chromosomal regions for further
analysis. For example, the region of the Y chromosome carrying
the SRY gene was pinpointed by examining 46,XX testicular DSD
patients with translocations of Y chromosome material to the X
chromosome and 46,XY CGD patients who had deletions of the Y
chromosome [15].
Copy number variation (CNV) is a term used to describe
rearrangements of the genome such as deletions and duplications
that result in an increase or decrease in the effective copy DNA
number. The development of microarrays has allowed copy
number analysis of the genome at a much finer resolution than was
possible by cytogenetic analysis. This approach has been used to
identify new disease genes in a range of disorders [16,17]. This
methodology has been applied to a few isolated DSD cases
[18,19], and has recently been used for studying diverse cohorts of
DSD patients[20,21]. Here we have used the Affymetrix Genome-
Wide Human SNP Array 6.0 to identify copy number variants in
23 patients with DSD due to 46,XY gonadal dysgenesis.
Materials and Methods
Patient Information
Twenty-three unrelated patients were diagnosed as having
46,XY GD. All patients with a diagnosis of XY complete gonadal
dysgenesis met the clinical criteria for this diagnosis, including
female external genitalia associated with a 46, XY karyotype, the
presence of Mullerian structures suggesting the lack of functional
testicular tissue, and high levels of gonadotropins suggesting a
primary gonadal failure caused by gonadal dysgenesis. Additional
clinical features, when present, (such as adrenal hypoplasia), are
indicated in Table 1.
No mutation was detected in the SRY coding sequence in any of
the 23 patients. For cases 14 and 21 (diagnosed with congenital
adrenal hypoplasia) the DAX1 and SF1 genes had also been
checked, and no mutation was identified. Genomic DNA from
cases 1–8 was isolated from lymphoblastoid cell lines using
standard methods. Genomic DNA from cases 9–23 was isolated
Table 1. 46,XY GD cases studied.
Case # Diagnosis Other clinical features Best candidate CNV (size/type) Candidate gene(s)
1 46,XY ovotesticular DSD
2 46,XY partial gonadal dysgenesis
3 46,XY complete gonadal dysgenesis
4 46,XY complete gonadal dysgenesis
5 46,XY partial gonadal dysgenesis
6 46,XY gonadal dysgenesis
7 46,XY partial gonadal dysgenesis
8 46,XY ovarian DSD
9 46,XY complete gonadal dysgenesis
10 46,XY complete gonadal dysgenesis Cleft palate, short stature Chr17:66200578-67393626
(1.193 Mb deletion)
SOX9
11 46,XY complete gonadal dysgenesis
12 46,XY complete gonadal dysgenesis Chr10:12382107-12770026
(388 kb duplication)
CAMK1D
13 46,XY complete gonadal dysgenesis ChrX:30131772- 30902339
(771 kb duplication)
DAX1 (NR0B1)
14 46,XY complete gonadal dysgenesis Adrenal Hypoplasia Congenita Chr8:11659702-11694481 (35 kb deletion) GATA4 (upstream of deletion)
15 46,XY complete gonadal dysgenesis Chr13:42568370-42610053
(42 kb duplication)
DNAJC15
16 46,XY complete gonadal dysgenesis Galactosemia
17 46,XY complete gonadal dysgenesis
18 46,XY complete gonadal dysgenesis Short stature
19 46,XY complete gonadal dysgenesis
20 46,XY complete gonadal dysgenesis Amelia
21 46,XY complete gonadal dysgenesis Adrenal Hypoplasia Congenita
22 46,XY complete gonadal dysgenesis IMAGE syndrome
23 46,XY complete gonadal dysgenesis
doi:10.1371/journal.pone.0017793.t001
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approved by the Human Research Ethics Committee of the
Royal Children’s Hospital Melbourne, Australia (# 22073D).
Affymetrix Microarray Analysis
All 23 DNA samples were hybridised onto the Affymetrix
Genome-Wide Human SNP Array 6.0 microarrays. These arrays
are composed of ,1.8 million markers, evenly targeted at single
nucleotide polymorphisms (SNPs) and other genomic regions
allowing the identification of copy number variants. Microarray
hybridisations were performed at the Australian Genome Research
Facility (Melbourne,Australia) following manufacturer’sinstructions.
Data were analysed using an early-access version of the
CRMAv2 total copy number (CN) method [22]. More precisely,
crosstalk between alleles in (SNPs) was controlled for and global
offset was removed from both SNPs and CN probes. The non-
polymorphic SNP signals were estimated as the median probe-pair
sum across replicated allele probe pairs (ignoring strand informa-
tion). PCR fragment-length effects in the non-polymorphic SNP
and CN probe signals were normalized. Total CNs were
calculated as the ratio of the non-polymorphic signals relative to
the robust average of all hybridizations. Chromosomal aberrations
were identified from log2 CN ratios using the Gain and Loss
Analysis of DNA (GLAD) 22. Duplications and deletions were
called using log2-thresholds of +0.3 and 20.3, respectively,
containing a minimum of 10 consecutive probes. The above
analysis was conducted using aroma.affymetrix [23].
Multiplex Ligation-dependent Probe Amplification
(MLPA)
CNVs identified by microarray analysis were validated by
Multiplex Ligation-dependent Probe Amplification (MLPA).
Probes were designed according to previously described criteria
[24]. Oligonucleotides were ordered from Sigma Genosys
(Australia), and were desalted without further purification. The
right hand oligonucleotide of each pair was 59 phosphorylated to
allow ligation to occur. Probe mixes were prepared by combining
each oligonucleotide so that all were present at a final
concentration of 4 fmol/mli nT E
24. MLPA reagents were
purchased from Fisher Biotec (Australia). MLPA reactions and
data analysis were performed as previously described [25,26].
DNA Sequencing
All primers used in sequencing were purchased from Sigma
Genosys (Australia). Sequencing was conducted at either the
Brisbane node of the Australian Genome Research Facility, or at
the Department of Pathology, University of Melbourne.
Putative SOX9 Enhancer
Putative SOX9 and SRY binding sites were identified using the
HMR Conserved Transcription Factor Binding Sites track on the
UCSC Genome Browser (hg18) with the default settings. PCR
primers were designed to amplify seven conserved genomic regions
(,0.5–1.5 kb in size) containing putative SOX9 and SRY binding
sites (table S1). The PCR fragments were cloned into
pGL4.10 minSOX9 (SOX9 minimal promoter [27] driving the
expression of firefly luciferase) upstream of the promoter.
Dual Luciferase Assays
Luciferase assays were performed in a recently developed
human cell line that expresses several markers of Sertoli cells [28],
e.g. SOX9, GATA4 and AMH, with10
5 cells plated in 24-well
plates. After 24 hours, the cells were transfected with the relevant
combination of plasmids using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Briefly, cells in each
well received 500 ng of luciferase reporter construct (pGL4-
minSOX9 with or without putative enhancer fragments), 200 ng
of transcription factor expression plasmid (pcDNA-SF1, SOX9,
SRY or empty pcDNA), and 50 ng of pRL-TK as transfection
control. After 48 hours, cells were harvested and luciferase activity
was measured using the Dual Luciferase Assay Kit (Promega) in a
TD-20/20 Luminometer (Turner Designs). Values were normal-
ized for transfection efficiency with respect to the effects of the
expression constructs on the empty pGL4-minSOX9 reporter
plasmid. Relative light units shown represent mean values 6SEM
obtained from at least four independent experiments performed in
duplicate.
RNA Isolation and Amplification
Gonads were dissected from E12.5-E15.5 Oct4-GFP mouse
embryos, dissociated with trypsin and FACS sorted into germ and
somatic fractions. Total RNA was isolated and amplified as
previously described [29].
Reverse Transcription and Real-Time PCR Analysis
Amplified RNA was reverse transcribed using the Transcriptor
High Fidelity cDNA synthesis kit (Roche, Mannheim, Germany).
Briefly, 100 ng amplified RNA was mixed with 2 ml of Random
Hexamer Primers, denatured at 65uC for 10 minutes and
immediately cooled on ice. Samples were reverse transcribed
following addition of 4 ml of 5x Transcriptor High Fidelity Reverse
Transcriptase Reaction Buffer, 0.5 ml of Protector RNase
Inhibitor, 2 ml of Deoxynucleotide Mix, 1 ml of DTT and 1 ml
of Transcriptor High Fidelity Reverse Transcriptase at 50uC for
30 minutes and inactivated at 85uC for 5 minutes.
Real-time PCR was performed in triplicate using 1 ng cDNA in
each 10 ml reaction, using the mouse Universal Probe Library
system (Roche), LightCycler 480 Probe Master mix (Roche) and a
LightCycler 480 instrument (Roche). All primers were designed
using the UPL Assay Design Centre (https://www.roche-applied-
science.com). Relative expression was determined using the
comparative CT method (DDCT), with samples normalised against
Sdha and expressed relative to the sample showing the lowest level
of expression for each experiment. In addition, the efficiency of
each primer/probe combination was determined using standard
curves.
Results
Microarray analysis
Twenty-three unrelated patients were diagnosed as having
46,XY GD. No mutation was detected in the SRY coding sequence
in any of the patients. We screened the genomic DNA of these
patients using the Affymetrix Genome-Wide Human SNP Array
6.0. A stringent threshold of at least 10 consecutive probes was set
for a CNV to be called. Using this criterion 1,498 high-confidence
CNV regions were identified, with no difference in the average
number or size of CNVs detected between DNA isolated from cell
lines or lymphocytes (Table 2).
Of the CNVs detected, 91% overlapped for at least 50%
with previously reported CNVs in the database of genomic
variants (DGV). To prioritise regions for further analysis we
focussed on rearrangements that a) covered or were within 500 kb
of genes known to be involved in gonad development; or b)
affected the coding region of RefSeq genes and were not listed in
the DGV.
CNV Analysis in Gonadal Dysgenesis
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Three cases had rearrangements that affected genes known to
play a role in sex determination or gonad development (for all
CNVs identified in these cases see table S2). Firstly, a 708 kb
duplication on the X chromosome was identified in case 13
(Figure 1a). This 46,XY DSD patient was diagnosed with
complete gonadal dysgenesis and no other clinical features were
reported. One of the seven genes contained within the duplicated
region was DAX1 (NR0B1), which has been previously been shown
to be duplicated in 46,XY complete gonadal dysgenesis.
Secondly, a deletion of 1.193 Mb approximately 300 kb
upstream of the SOX9 gene was identified in case 10 (Figure 1b).
This 46,XY individual had been diagnosed with complete gonadal
dysgenesis. The only other clinical features reported were a cleft
palate and height at the 3
rd centile. This is very unusual as
rearrangements and mutations affecting SOX9 normally result in
patients with campomelic dysplasia (deformity of chondrogenesis)
and in some 46,XY cases, gondal dysgenesis. SOX9 is known to
play a critical role in testis development, and other rearrangements
upstream of this gene have been described in 46,XY DSD (or
CGD) patients. The deletion described here did not cover the
orthologous sequence of the recently identified TESCO element in
mouse, which was proposed to act as an enhancer in regulating
SOX9 expression in the gonad [14]. The orthologous human
TESCO region was sequenced in the index patient, and no
mutations or polymorphisms were identified (data not shown). The
gonadal dysgenesis observed in this patient suggests that one or
more testis-specific regulatory elements of SOX9 are contained
within the 1.2 Mb deletion. In an attempt to identify such regions
we performed a bioinformatic analysis of the 1.2 Mb region,
searching for potential SRY/SOX9 binding sites that were
conserved in human, mouse and rat. In total we identified seven
such regions, hereafter referred to as enh1–7 (Figure 2a). Each of
these regions was PCR amplified and cloned into a pGL4 vector
containing the human SOX9 minimal promoter. Following
transfection into a human Sertoli cell line, Addition of SF1,
SRY or SOX9 led to a statistically higher level of enhancer activity
for enh3, 4, 5, 6 and 7 for at least one of the transcription factors,
with enh5 affected by all three (Figure 2b).
Thirdly, a 35 kb deletion including NEIL2 was identified in case
14 (Figure 1c and Figure 3). Although there is no known role for
NEIL2 in sex determination or differentiation, the deletion was
immediately downstream of GATA4, a gene previously implicated
in gonad development in the mouse. Low microarray probe
density around the deletion breakpoint made it unclear whether
the GATA4 39UTR was included in the deletion. Several MLPA
probes were designed in the intervening space, and analysis
showed that the deletion did not extend into GATA4 39 UTR
sequence (data not shown). The deletion was not present in the
father or unaffected sister (DNA from the mother was not available
for analysis), and sequence analysis did not reveal any variants in
either NEIL2 or GATA4 in the index patient.
Rearrangements affecting candidate gonadal genes
Several previously unreported CNVs were identified that
affected the coding region of genes not currently associated with
gonad development. The genes affected were GPR83, ACBD7,
CAMK1D, OLAH, NEIL2 and DNAJC15 (table S3). To assess the
potential of these genes to be involved in DSD, expression analysis
Table 2. CNV analysis using the Affymetrix 6.0 array.
Cases 1–8 (derived
from cell lines)
Cases 9–23 (derived
from lymphocytes)
Number of samples 8 15
CNVs/genome 64 66
Min/max/median
CNV size (kb)
0.4/1577/20 0.3/1778/19
.50% overlap
with known CNVs
92% 90%
doi:10.1371/journal.pone.0017793.t002
Figure 1. CNV analysis of three 46,XY GD cases using the AROMA algorithm. Data are plotted along each chromosome, with each point
represents the copy number estimate of an individual probe. The horizontal solid black line denotes the predicted copy number of the genomic
region. For each panel coverage of 2 Mb is shown, with numbers on the horizontal axis corresponding to the March 2006 human reference sequence
(hg18). A) Duplication of ,708 kb on the X-chromosome in case 13. B) Deletion of 1.193 Mb on chromosome 17 in case 10. C) Deletion of 35 kb on
chromosome 8 in case 14.
doi:10.1371/journal.pone.0017793.g001
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purified somatic cells isolated from male and female mouse gonads
at the time of sex differentiation. Two genes (Dnajc15 and Camk1d)
showed sexually dimorphic expression in the somatic cells
(Figure 4). Dnajc15 was expressed more highly in the female
gonad than the male (p,0.005 at E13.5, E14.5, E15.5).
Conversely, Camk1d expression was significantly higher in the
developing male gonad when compared to the female gonad
(p,0.05 at E13.5, p,0.005 at E15.5).
Discussion
We have used the Affymetrix Genome-Wide Human SNP
Array 6.0 to identify deletions and duplications in a cohort of 23
patients with 46,XY GD. A relatively stringent threshold of 10
consecutive probes was set before a CNV was considered genuine.
However, despite this stringent criterion over 65 CNVs per sample
were detected by the microarray. Discriminating causative CNVs
from benign polymorphisms was complicated by the incomplete
knowledge of polymorphic CNVs [30]. When comparing our
findings with those reported in the database of genomic variants
[31], over 90% overlapped with previously identified rearrange-
ments for at least half the affected region. A confounding issue
associated with any mutation screening study, but particularly
relevant for DSD, is parent of origin effect. As gonad development
in males and females involves distinct genes and pathways, a given
variant might disrupt one gonad specific pathway, leading to DSD,
whilst having no effect on the development of the other gonad
type. It is therefore not possible to completely exclude CNVs that
have been inherited (particularly from the parent with the opposite
sex chromosome composition or that have previously been
identified in apparently healthy individuals. Therefore, in addition
to previously undescribed CNVs affecting RefSeq genes we have
also chosen to examine rearrangements overlapping or in
Figure 2. Deletion (1.193 Mb) on chromosome 17, upstream of SOX9 in a patient with 46,XY GD. a) The location and extent of the
1.193 Mb deletion on chromosome 17, upstream of SOX9 identified in case 10. The numbers at the top of the figure correspond to nucleotide
position based on the March 2006 human reference sequence (hg18). Also shown are structural variants within this region that are listed in the
database of genomic variants. (http://projects.tcag.ca/variation/). The numbered arrows indicate the positions of the seven potential gonad specific
regulatory elements (enh1–7) that were cloned into reporter constructs. The position of the orthologous sequence corresponding to the mouse
TESCO sequence is indicated by an asterisk (*). b). Reporter construct analysis of SOX9 regulatory regions. Effect of selected transcription factorso n
luciferase activity driven by putative gonad regulatory regions (enh1–7) inserted upstream of the minimal SOX9 promoter (sox prom). Results are
given as relative activation of the reporter by the expression constructs (SF1, SOX9, SRY) compared with the empty vector (pcDNA3). Data represent
mean values 6SEM obtained from at least four independent experiments. Statistical analysis was performed with a 2-tailed t-test. ** p,0.005;
*p ,0.05.
doi:10.1371/journal.pone.0017793.g002
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irrespective of whether or not they overlap with previously
reported CNVs.
DAX1 (NROB1)
The first rearrangement was a 708 kb duplication containing
DAX1 in case 13. Other 46,XY GD patients have been described
with duplications overlapping the same region of the X
chromosome [19,32]. DAX1 shows sexually dimorphic gonadal
expression, being downregulated in the developing testis [33].
Studies in mouse models support Dax1 as having both pro-testis
[34,35] and anti-testis functions [33]. These studies indicate that
a critical level of Dax1 is required for proper testis cord formation
– levels above or below this level interfere with the early stages of
testicular differentiation (e.g, a duplication interferes with SRY
function, while a loss of function retards early cord organisation
on a susceptible genetic background). As testis development
proceeds, DAX1 is down-regulated, that is it antagonises the
SF1/WT1/SOX9 activation of AMH. Hence, DAX1 has
dynamic effects on the developing testis that changes over
time.[36]
SOX9
The second rearrangement affecting a known testis gene was a
1.2 Mb deletion, approximately 300 kb upstream of SOX9 in case
10. Several studies have demonstrated that correct expression of
SOX9 is critical for appropriate development of chondrogenic
tissue [37] and testes [38]. A large duplication encompassing
SOX9 was reported in a single, mosaic case of 46,XX testicular
DSD [39]. This rearrangement presumably led to increased levels
of SOX9 expression and testis development. Mutations within
and outside of SOX9 are known to cause the bone disorder
campomelic dysplasia (CD), which in approximately 70% of cases
is associated with 46,XY GD. Non-overlapping deletions and
translocation breakpoints up to 1 Mb from the SOX9 coding
sequence have been identified in CD patients, with and without
46,XY GD), suggesting that there are multiple regulatory
elements controlling SOX9 expression[40,41,42,43,44,
45,46,47,48]. Case 10 is remarkable as it is the first reported
case of a rearrangement affecting the SOX9 locus in a 46,XY GD
individual in the absence of campomelic or acampomelic
dysplasia. The only clinical features reported other than gonadal
dysgenesis were short height (3
rd centile) and a cleft palate. The
deletion in case 10 does not overlap with the cis-regulatory
element identified in a study of Pierre-Robin sequence patients
[49], a disorder that presents with several clinical features
including cleft palate. The close proximity (,13 kb from)
however, suggests that a position effect altering the function of
this putative enhancer may underlie the cleft palate observed in
case 10.
The lack of any bone pathology consistent with CD would
suggest that the regulatory element(s) necessary for appropriate
SOX9 expression during skeletal development are present outside
the deleted region in this patient. Furthermore, it suggests that
mutations affecting SOX9 regulation in the gonad may have been
underestimated as a cause of gonadal dysgenesis in the absence of
CD. However, we cannot exclude that the deletion has created a
new regulatory element, or relocated an existing sequence that can
function as a tissue-specific silencer. This would be analogous to a
previously described insertion/deletion upstream of the Sox9 locus
in a XX sex reversed transgenic mouse [50]. In that instance it was
originally thought that the deletion removed a gonad-specific
suppressive element, but subsequent studies showed that the
inserted material was capable of driving Sox9 expression in the
mouse gonad [51].
In case 10 the deletion upstream of SOX9 did not extend into
the orthologous human sequence of a recently identified
enhancer that has been proposed to regulate Sox9 expression in
the developing mouse gonad [14]. In mouse a 3.2 kb sequence
(TES – testis-specific enhancer) ,10 kb upstream of Sox9 was
defined, with 1.4 kb of this (TESCO – TES core element) as the
critical region. Functional studies showed that the TESCO
sequence was capable of acting as an enhancer in an Sry- and
Sf1-dependent manner, consistent with Sox9 being a direct
downstream target of Sry. Sf1 and Sry were shown to be required
for enhancer activity, as mutating their binding sites within the
TES sequence eliminated enhancer activity. However, it has not
yet been demonstrated that deletion of the TESCO region is
sufficient by itself to cause male to female sex reversal. Indeed, a
recent study of 66 46,XY gonadal dysgenesis patients did not
identify any mutations in the genomic region orthologous to
TESCO [52]. We sequenced this region in case 10, and did not
identify any sequence variants. As no point mutations have been
identified in the TESCO region of 46,XY patients, and loss-of-
function rearrangements outside this region have been identified
in other 46,XY GD patients, regulatory elements other than or in
addition to TESCO are likely to be involved in gonad-specific
SOX9 expression in humans.
Common bioinformatic approaches to identify potential
regulatory elements include examining sequences that show
significant interspecies conservation, or sequences containing
consensus binding site motifs for transcription factors. Previous
Figure 3. Deletion (35 kb) on chromosome 8, downstream of GATA4 in a patient with 46,XY GD. The minimum size of the deletion as
defined by array analysis is shown. The numbers at the top of the figure correspond to nucleotide position based on the March 2006 human
reference sequence (hg18). Also shown is an inversion covering this region that is listed in the database of genomic variants (http://projects.tcag.ca/
variation/).
doi:10.1371/journal.pone.0017793.g003
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enhancers in mice [53,54]. We selected seven human DNA
sequences within the region deleted in case 10 that are conserved
between human, mouse and rat and contain putative SRY/SOX9
binding sites. Co-transfecting reporter constructs containing each
of these sequences together with SRY, SF1 or SOX9 into a human
Sertoli cell line revealed that five of the seven regions showed
significantly increased luciferase expression when compared to the
SOX9 minimal promoter only. Enhancer 5 (enh5) was the only
one to show a significant increase in luciferase expression for each
of the transcription factors, and was the only one to respond to
SF1. Enh6 responded only to SRY, whereas each of enh3, enh4
and enh7 responded to both SOX9 and SRY. These DNA
sequences are the first putative SOX9 gonad enhancers identified
in humans, and are targets for mutation screening in a larger
cohort of 46,XY DSD GD patients.
Figure 4. Expression analysis of Camk1d and Dnajc15 in developing mouse gonads. Expression analysis was performed on cDNA from
sorted GFP- (somatic) cells derived from male and female mouse gonads, embryonic days 12.5–15.5. The data is normalised such that the lowest
expression is 1.0, and represent mean values 6SEM from three independent experiments. Shown here are the expression patterns for a) Camk1d and
b) Dnajc15. Comparisons between male and female expression for Camk1d and Dnajc15 were performed with a 2-tailed t-test. ** p,0.005; * p,0.05.
doi:10.1371/journal.pone.0017793.g004
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We identified a 35 kb deletion that completely removed
NEIL2 in case 14. Although there is no evidence supporting a
role for NEIL2 in testis determination, the deletion is
immediately 39 of the neighbouring GATA4 gene. In mice,
mutations of Gata4 that interfere with Gata4-Fog2 interaction
lead to gonadal abnormalities in specific strains of XY mice [55].
It has been shown that Gata4 also acts synergistically with Wt1
in activating both the Sry and Amh promoters.[56] Amh (anti-
Mu ¨llerian hormone, also known as Mu ¨llerian inhibiting
substance) is responsible for the regression of the Mu ¨llerian
structures that would otherwise form the female internal
reproductive tract. Mutations affecting the coding sequence of
GATA4 in humans are associated with cardiac malformations,
with no mutations as yet associated with gonadal dysgenesis. As
the rearrangement we have identified does not affect GATA4
coding sequence, we would not necessarily expect cardiac
malformations as a consequence of the deletion. It is possible
that a regulatory element controlling GATA4 expression in the
developing gonad is either removed or relocated by the deletion.
This is analogous to the situation we recently described for
rearrangements nearby the SOX3 coding sequence in 46,XX
males which affected gene regulation [57].
While this manuscript was under revision there was a report
describing a family where a GATA4 missense mutation segregated
with congenital heart disease and 46,XY DSD[58]. There were
three affected 46,XY males with DSD. All three patients had
inguinal gonads (in one individual the gonads were removed
surgically as they were dysgenic) and two had hypospadias. In
addition one of the males had a systolic murmur without any atrial
septal defect. Two 46,XX females within the family had congenital
heart conditions, although there was no sign of gonadal
dysfunction.
The authors proposed that the DSD observed in 46,XY carriers
of the GATA4 mutation was due to a loss-of-function effect on
GATA4 in the developing gonad, interfering with its ability to
interact with FOG2 and disturbing activation of the AMH
promoter together with NR5A1. This finding further strengthens
the case for the deletion we observed downstream of GATA4 in
case 14 as being causative for DSD.
Other CNVs
We identified several other previously unreported CNVs that
affected the coding region of genes. To assess the potential role of
any of these genes in gonadal development we examined their
expression levels in FACS sorted somatic cells from E12.5 to E15.5
mouse gonads. The advantage of using a purified cell population
for expression analysis is that testis determining genes are expected
to be enriched specifically in the somatic component [1]. Two
genes (Dnajc15 and Camk1d) showed sexually dimorphic expression
in somatic cells. It is interesting to note that the two genes show
opposite patterns of expression, as Camk1d is higher in the male
gonad vs the female whereas Dnajc15 is higher in the female.
Although this is apparently contradictory in patients with similar
clinical features, it may be that the genes have opposite roles in
testis development i.e. one has a positive effect and the other has an
inhibitory function.
Dnajc15 has been suggested to be involved in pronephros
development in Xenopus embryos [59], and Camk1d has been
associated with type 2 diabetes [60]. Further analysis needs to
conducted on these genes to define their potential role in gonad
development.
Our analysis of 23 patients identified a large number of
previously unidentified CNVs outside coding sequence. Unfortu-
nately it is currently impractical to assay the effects of each of these
in mouse models. It is possible that there may be as yet
unidentified genes or non-coding RNAs within these regions.
Further analysis of potential regulatory elements looking at
markers such as histone modifications [61] or DNaseI hypersen-
sitive sites [62,63] in chromatin are powerful approaches to
prioritise regions for more detailed analysis.
There are a number of possible explanations for the remaining
patients in whom no causative mutations were identified. Point
mutations in the known sex determining genes may account for
some cases, although previous studies suggest that these will
explain less than 20% of all cases of 46,XY GD [11]. Smaller
rearrangements, within these or other genes that are beneath the
resolution of the microarray will have been missed in this study. In
addition, there may be point mutations in other, as yet
unidentified sex determining genes, and it is likely that mutations
affecting regulatory elements in non-coding regions of the genome
are responsible for a number of cases.
In conclusion, we have identified a number of potentially
causative genomic rearrangements in patients with 46,XY GD.
These include a duplication of DAX1 (NROB1) and a deletion
upstream of SOX9 which potentially contain novel gonad-
specific gene regulatory elements. In addition, we found a
deletion in close proximity to GATA4. This rearrangement is the
first evidence in humans suggesting that mutations affecting
GATA4 expression may be involved in 46,XY GD. Our
findings suggest that rearrangements of non-coding sequences
that disturb gene regulation may account for significant
proportion of DSD cases, suggesting that new strategies will
be required for increasing diagnostic yields. Characterising the
regulatory elements responsible for the correct spatial and
temporal expression of these genes will be necessary to obtain a
true picture of the gene networks responsible for gonad
differentiation and development.
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